EMA Authorised: Qtern (saxagliptin;dapagliflozin propanediol monohydrate) — Astra Zeneca AB

View source ↗

Summary

The European Medicines Agency authorised Qtern, a fixed-dose combination of saxagliptin and dapagliflozin propanediol monohydrate, for type 2 diabetes mellitus.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin propanediol monohydrate (dapagliflozin propanediol monohydrate)
• QTERN (saxagliptin and dapagliflozin)
• Saxagliptin (saxagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2;Diabetes Mellitus;Nutritional and Metabolic Diseases;Metabolic Diseases;Glucose Metabolism Disorders. MAH: Astra Zeneca AB. Decision date: 12/03/2026